Consensus Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:13:16 2025-12-15 pm EST			5-day change	1st Jan Change
169.78 ^USD	+1.36%		+0.70%	+38.14%

Dec. 11	Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing	MT
Dec. 10	This Is Decision Day

Evolution of the Average Target: Jazz Pharmaceuticals plc

Evolution of the Target Price: Jazz Pharmaceuticals plc

Changes in Analyst Recommendations: Jazz Pharmaceuticals plc

78b13a1d99cb66dfdd.ccuxwWnxLWk5C-TGvFTYayJrTV1-fYLR-sgujs7oSvg.GqD3sz2dXTZtOa6F-RKCRncnLGoZL8Cezblj6r2iCa8W_NiYJZN3AHZfrQ~9e845dc3bd997ebe42c2fe2f2ac179fe

Analysts' recommendations: Jazz Pharmaceuticals plc

Dec. 10	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
Nov. 24	Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says	MT
Nov. 24	UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Raises Price Target to $188 From $163	MT
Nov. 19	Truist Adjusts Price Target on Jazz Pharmaceuticals Public to $220 From $205, Maintains Buy Rating	MT
Nov. 18	Deutsche Bank Raises Price Target on Jazz Pharmaceuticals to $210 From $173, Keeps Buy Rating	MT
Nov. 18	Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast…
Nov. 06	RBC Raises Price Target on Jazz Pharmaceuticals to $155 From $151, Keeps Outperform Rating	MT
Nov. 06	Morgan Stanley Lifts Price Target on Jazz Pharmaceuticals to $185 From $183, Keeps Overweight Rating	MT
Oct. 20	Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says	MT
Oct. 20	Morgan Stanley Raises Price Target on Jazz Pharmaceuticals to $180 From $167, Keeps Overweight Rating	MT
Oct. 09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
Oct. 09	BofA Adjusts Price Target on Jazz Pharmaceuticals Public to $230 From $225	MT
Oct. 03	Deutsche Bank Raises Price Target on Jazz Pharmaceuticals to $173 From $170, Keeps Buy Rating	MT
Oct. 02	Jazz Pharma, Roche's combination therapy for lung cancer gets US approval	RE
Oct. 02	US FDA approves Jazz Pharma's therapy for lung cancer	RE
Aug. 28	Truist Raises Price Target on Jazz Pharmaceuticals to $205 From $200, Keeps Buy Rating	MT
Aug. 28	RBC Raises Price Target on Jazz Pharmaceuticals to $151 From $145, Keeps Outperform Rating	MT
Aug. 07	Deutsche Bank Adjusts Jazz Pharmaceuticals Public Price Target to $154 From $152, Maintains Buy Rating	MT
Aug. 06	RBC Cuts Price Target on Jazz Pharmaceuticals to $145 From $167, Keeps Outperform Rating	MT
Jul. 15	Jazz Pharmaceuticals Stock Offers Buying Opportunity After Slump, Deutsche Bank Says	MT
Jul. 15	Deutsche Bank Initiates Jazz Pharmaceuticals at Buy With $152 Price Target	MT
Jul. 07	RBC Lowers Price Target on Jazz Pharmaceuticals to $167 From $172, Keeps Outperform Rating	MT
May. 07	Morgan Stanley Cuts Price Target on Jazz Pharmaceuticals to $166 From $183, Keeps Overweight Rating	MT
Apr. 03	RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating	MT
Mar. 07	UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JAZZ PHARMACEUTICALS PLC					+27.16%
	ELI LILLY AND COMPANY					+4.69%
	JOHNSON & JOHNSON					-2.48%
	ABBVIE INC.					+9.63%
	ROCHE HOLDING AG					+2.05%
	ASTRAZENECA PLC					+12.08%
	NOVARTIS AG					+2.06%
	MERCK & CO., INC.					+7.14%
	NOVO NORDISK A/S					+22.46%
	AMGEN INC.					+2.56%
	Average					+8.74%
	Weighted average by Cap.					+5.66%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

167.50USD

Average target price

213.00USD

Spread / Average Target

+27.16%

High Price Target

247.00USD

Spread / Highest target

+47.46%

Low Price Target

188.00USD

Spread / Lowest Target

+12.24%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Truist Securities
Deutsche Bank Securities
RBC Capital Markets
Morgan Stanley
BofA Securities
Wells Fargo Securities
Needham & Co.
JPMorgan Chase
Piper Sandler
Stifel Nicolaus
HC Wainwright
Barclays
Baird
Raymond James
Cantor Fitzgerald
Guggenheim
Goldman Sachs
SVB Securities LLC
BMO Capital
SVB Leerink
Citigroup
J.P. Morgan Chase